Metropolis Healthcare (NSE:METROPOLIS) ROCE %: 17.23% (As of Mar. 2026)


NSE:METROPOLIS Metropolis Healthcare Ltd NSE:METROPOLIS
95 GF Score
Price ₹567.95
GF Value ₹588.25
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Metropolis Healthcare ROCE %?

Metropolis Healthcare NSE:METROPOLIS +1.41% 95 ROCE % is 17.23% as of Mar. 2026. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 95/100 and a GF Value™ of ₹588.25 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Metropolis Healthcare's annualized ROCE % for the quarter that ended in Mar. 2026 was 17.23%.

Metropolis Healthcare  (NSE:METROPOLIS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Metropolis Healthcare ROCE % Related Terms

Metropolis Healthcare ROCE % Historical Data

* Premium members only.

The historical data trend for Metropolis Healthcare's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metropolis Healthcare ROCE % Chart

Metropolis Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.86 17.39 15.49 14.53 16.80

Metropolis Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.33 16.89 18.15 14.88 17.23
NSE:METROPOLIS
95GF Score
Metropolis Healthcare Ltd NSE:METROPOLIS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metropolis Healthcare ROCE % Calculation

Metropolis Healthcare's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=2837.194/( ( (18673.402 - 2943.342) + (21380.546 - 3340.221) )/ 2 )
=2837.194/( (15730.06+18040.325)/ 2 )
=2837.194/16885.1925
=16.80 %

Metropolis Healthcare's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=3107.82/( ( (0 - 0) + (21380.546 - 3340.221) )/ 1 )
=3107.82/( ( 0 + 18040.325 )/ 1 )
=3107.82/18040.325
=17.23 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 17.23% mean?
Metropolis Healthcare (NSE:METROPOLIS) has a ROCE % of 17.23% as of Mar. 2026.
Is Metropolis Healthcare's ROCE % too high?
Metropolis Healthcare's current ROCE % is 17.23%. Overall, Metropolis Healthcare has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's ROCE % compare to TMO and DHR?
Metropolis Healthcare's ROCE % of 17.23% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Metropolis Healthcare's current ROCE % is 17.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹588.25, compared to a current price of ₹567.95 — trading 3.5% below its estimated fair value. The current ROCE % is 17.23%. Metropolis Healthcare's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current ROCE % is 17.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?

Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued. The current stock price of ₹567.95 is trading 3.5% below its estimated GF Value™ of ₹588.25. GuruFocus considers Metropolis Healthcare to be Fairly Valued.

Key valuation signals for NSE:METROPOLIS:

  • ROCE %: 17.23%
  • GF Value™: ₹588.25 vs. price of ₹567.95 (3.5% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Metropolis Healthcare Business Description

Other Exchanges 542650:India
Address Dr. Annie Besant Road, 4th Floor, East Wing, Plot-254 B, Nirlon House, Worli, Mumbai, MH, IND, 400 030
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
95GF Score

Get the complete analysis for NSE:METROPOLIS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹567.95
Price
₹588.25
GF Value